Cantor Fitzgerald Downgrades Cerevel Therapeutics Hldg to Neutral, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has downgraded Cerevel Therapeutics Holdings (CERE) from Overweight to Neutral, while increasing the price target from $38 to $45.

December 07, 2023 | 10:50 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald downgraded Cerevel Therapeutics Holdings to Neutral but raised the price target to $45, indicating mixed sentiment.
The downgrade to Neutral suggests that Cantor Fitzgerald believes CERE is now fairly valued or has limited upside potential based on current information. However, the increase in the price target to $45 implies a belief in the company's solid fundamentals or future prospects. This mixed sentiment may lead to a neutral short-term impact on the stock price as the market digests both the downgrade and the higher price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100